SCTX (Scribe Therapeutics) Interest Expense: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $29.74
! 1 Warning Sign
View Full Analysis

What is Scribe Therapeutics Interest Expense?

Scribe Therapeutics SCTX -0.20% 8 Interest Expense is $ Mil as of Dec. 2025. GuruFocus rates SCTX with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scribe Therapeutics's interest expense for the six months ended in Dec. 2025 was $ -2.39 Mil. Scribe Therapeutics does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in Dec. 2025.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scribe Therapeutics's Operating Income for the six months ended in Dec. 2025 was $ -26.07 Mil. Scribe Therapeutics's Interest Expense for the six months ended in Dec. 2025 was $ -2.39 Mil. Scribe Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scribe Therapeutics  (NAS:SCTX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scribe Therapeutics's Interest Expense for the six months ended in Dec. 2025 was $-2.39 Mil. Its Operating Income for the six months ended in Dec. 2025 was $-26.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was $4.80 Mil.

Scribe Therapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Scribe Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Scribe Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics Interest Expense Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
Interest Expense
-2.38 -2.39

Scribe Therapeutics Semi-Annual Data
Dec24 Dec25
Interest Expense -2.38 -2.39
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $ Mil mean?
Scribe Therapeutics (SCTX) has a Interest Expense of $ Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' Interest Expense too high?
Scribe Therapeutics' current Interest Expense is $ Mil. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' Interest Expense compare to ARTV and CABA?
Scribe Therapeutics' Interest Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current Interest Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current Interest Expense of $ Mil. The current Interest Expense is $ Mil. Scribe Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current Interest Expense is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.74
Price